Abstract
Background The natural history of SARS-CoV-2 infection and transmission dynamics may have changed as SARS-CoV-2 has evolved and population immunity has shifted.
Methods Household contacts, enrolled from two multi-site case-ascertained household transmission studies (April 2020–April 2021 and September 2021–September 2022), were followed for 10–14 days after enrollment with daily collection of nasal swabs and/or saliva for SARS-CoV-2 testing and symptom diaries. SARS-CoV-2 virus lineage was determined by whole genome sequencing, with multiple imputation where sequences could not be recovered. Adjusted infection risks were estimated using modified Poisson regression.
Findings 858 primary cases with 1473 household contacts were examined. Among unvaccinated household contacts, the infection risk adjusted for presence of prior infection and age was 58% (95% confidence interval [CI]: 49–68%) in households currently exposed to pre-Delta lineages and 90% (95% CI: 74–100%) among those exposed to Omicron BA.5 (detected May – September 2022). The fraction of infected household contacts reporting any symptom was similarly high between pre-Delta (86%, 95% CI: 81–91%) and Omicron lineages (77%, 70–85%). Among Omicron BA.5-infected contacts, 48% (41–56%) reported fever, 63% (56–71%) cough, 22% (17–28%) shortness of breath, and 20% (15–27%) loss of/change in taste/smell.
Interpretation The risk of infection among household contacts exposed to SARS-CoV-2 is high and increasing with more recent SARS-CoV-2 lineages. This high infection risk highlights the importance of vaccination to prevent severe disease.
Funding Funded by the Centers for Disease Control and Prevention and the Food and Drug Administration.
Key points
- Monitoring the transmissibility and symptomatology of SARS-CoV-2 lineages is important for informing public health practice and understanding the epidemiology of COVID-19; household transmission studies contribute to our understanding of the natural history of SARS-CoV-2 infections and the transmissibility of SARS-CoV-2 variants.
- The Omicron BA.5 sub-lineage is highly transmissible, similar to previous Omicron sub-lineages.
- Over 80% of infected household contacts reported at least 1 symptom during their infection and the proportion of household contacts with asymptomatic infection did not differ by SARS-CoV-2 variant. The most common symptom was cough. Change in taste or smell was more common in Omicron BA.5 infections, compared to previous Omicron sub-lineages, but less common compared to pre-Delta lineages.
- The high infection risk among household contacts supports the recommendations that individuals maintain up-to-date and lineage-specific vaccinations to mitigate further risks of severe disease.
Competing Interest Statement
ASL discloses personal fees to Sanofi and Roche outside the submitted work. HQM discloses grants from Seqirus outside the submitted work. YM discloses grants from Pfizer outside the submitted work. SR discloses grants from Biofire and consulting fees from Seqirus outside the submitted work. EAB discloses grants from Seqirus outside the submitted work. LS discloses consulting fees from CF foundation outside the submitted work. EA discloses grants from Pfizer and fees from Hillevax and Moderna outside the submitted work. SD discloses grants from Pfizer and Biofizer, and fees from Biofire, Diasorin Molecular, and Karius outside the submitted work. DP discloses grants from Pfizer and Roche outside the submitted work. CL discloses grants from AbbVie, AstraZeneca, bioMeriuex, Endpoint Helath, and Entegrion Inc, and investments in Bioscape Digital outside the submitted work. NH discloses grants from Quidel and Sanofi, and honoraria from Genentech outside the submitted work. CG discloses grants from Campbell Alliance/Syneos Health, Merck, Pfizer, and Sanofi, and fees from Sanofi and Pfizer outside the submitted work. No other authors disclose potential competing interests.
Funding Statement
Funded by the Centers for Disease Control and Prevention and the Food and Drug Administration.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Vanderbilt University Medical Center, Marshfield Clinic Research Institute, or Westat IRBs gave ethical approval for this work. CDC determined these activities were conducted consistent with applicable federal law and CDC policy (see 45 C.F.R. part 46; 21 C.F.R. part 56).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author’s Note: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
